The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling

Background The existing estimate of the global burden of latent TB infection (LTBI) as “one-third” of the world population is nearly 20 y old. Given the importance of controlling LTBI as part of the End TB Strategy for eliminating TB by 2050, changes in demography and scientific understanding, and progress in TB control, it is important to re-assess the global burden of LTBI. Methods and Findings We constructed trends in annual risk in infection (ARI) for countries between 1934 and 2014 using a combination of direct estimates of ARI from LTBI surveys (131 surveys from 1950 to 2011) and indirect estimates of ARI calculated from World Health Organisation (WHO) estimates of smear positive TB prevalence from 1990 to 2014. Gaussian process regression was used to generate ARIs for country-years without data and to represent uncertainty. Estimated ARI time-series were applied to the demography in each country to calculate the number and proportions of individuals infected, recently infected (infected within 2 y), and recently infected with isoniazid (INH)-resistant strains. Resulting estimates were aggregated by WHO region. We estimated the contribution of existing infections to TB incidence in 2035 and 2050. In 2014, the global burden of LTBI was 23.0% (95% uncertainty interval [UI]: 20.4%–26.4%), amounting to approximately 1.7 billion people. WHO South-East Asia, Western-Pacific, and Africa regions had the highest prevalence and accounted for around 80% of those with LTBI. Prevalence of recent infection was 0.8% (95% UI: 0.7%–0.9%) of the global population, amounting to 55.5 (95% UI: 48.2–63.8) million individuals currently at high risk of TB disease, of which 10.9% (95% UI:10.2%–11.8%) was isoniazid-resistant. Current LTBI alone, assuming no additional infections from 2015 onwards, would be expected to generate TB incidences in the region of 16.5 per 100,000 per year in 2035 and 8.3 per 100,000 per year in 2050. Limitations included the quantity and methodological heterogeneity of direct ARI data, and limited evidence to inform on potential clearance of LTBI. Conclusions We estimate that approximately 1.7 billion individuals were latently infected with Mycobacterium tuberculosis (M.tb) globally in 2014, just under a quarter of the global population. Investment in new tools to improve diagnosis and treatment of those with LTBI at risk of progressing to disease is urgently needed to address this latent reservoir if the 2050 target of eliminating TB is to be reached.

[1]  H. Jenkins,et al.  Smear positivity in paediatric and adult tuberculosis: systematic review and meta-analysis , 2016, BMC Infectious Diseases.

[2]  Christopher Dye,et al.  The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. , 2003, Archives of internal medicine.

[3]  C. Dye,et al.  Trends in tuberculosis incidence and their determinants in 134 countries. , 2009, Bulletin of the World Health Organization.

[4]  G. Cauthen,et al.  Annual risk of tuberculous infection. 1988. , 2002, Bulletin of the World Health Organization.

[5]  R. Chaisson,et al.  Latent Mycobacterium tuberculosis infection. , 2015, The New England journal of medicine.

[6]  P. Dodd,et al.  Burden of childhood tuberculosis in 22 high-burden countries: a mathematical modelling study. , 2014, The Lancet. Global health.

[7]  M Elizabeth Halloran,et al.  Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics , 2009, Proceedings of the National Academy of Sciences.

[8]  J. Janssens,et al.  An ecological analysis of incidence of tuberculosis and per capita gross domestic product , 2008, European Respiratory Journal.

[9]  Christopher Gilpin,et al.  WHO's new End TB Strategy , 2015, The Lancet.

[10]  P. Kouw,et al.  Risk of tuberculosis after recent exposure. A 10-year follow-up study of contacts in Amsterdam. , 2014, American journal of respiratory and critical care medicine.

[11]  T. Robinson,et al.  Sustainable Development Goals , 2016 .

[12]  F. van Leth,et al.  Prevalence of tuberculous infection and incidence of tuberculosis: a re-assessment of the Styblo rule. , 2008, Bulletin of the World Health Organization.

[13]  B. Ghassemieh,et al.  The Prevalence of Latent Tuberculosis Infection in the United States. , 2016, American journal of respiratory and critical care medicine.

[14]  Christopher Dye,et al.  Global Burden of Tuberculosis: Estimated Incidence, Prevalence, and Mortality by Country , 1999 .

[15]  Daniel E. Zak,et al.  A prospective blood RNA signature for tuberculosis disease risk , 2016, The Lancet.

[16]  A. Dirksen,et al.  Molecular evidence of endogenous reactivation of Mycobacterium tuberculosis after 33 years of latent infection. , 2002, The Journal of infectious diseases.

[17]  P E Fine,et al.  The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection , 1997, Epidemiology and Infection.

[18]  M. Pai,et al.  Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. , 2012, The Lancet. Infectious diseases.

[19]  R. Wilkinson,et al.  The ongoing challenge of latent tuberculosis , 2014, Philosophical Transactions of the Royal Society B: Biological Sciences.

[20]  Masahiro Narita,et al.  Revisiting rates of reactivation tuberculosis: a population-based approach. , 2010, American journal of respiratory and critical care medicine.

[21]  Elena Losina,et al.  Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  C. Dye,et al.  Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness , 2006, The Lancet.

[23]  C. Sismanidis,et al.  Global burden of drug-resistant tuberculosis in children: a mathematical modelling study. , 2016, The Lancet. Infectious diseases.

[24]  S. P. Akpabio World Health Organisation , 1983, British Dental Journal.

[25]  M. Pai,et al.  Gamma Interferon Release Assays for Detection of Mycobacterium tuberculosis Infection , 2014, Clinical Microbiology Reviews.

[26]  G. Weisenborn United Nations Sustainable Development Goals , 2018 .

[27]  Guidelines on the management of latent tuberculosis infection , 2014 .

[28]  C. Dye,et al.  Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. , 1999, JAMA.

[29]  S. Radhakrishna,et al.  The development of clinical tuberculosis following infection with tubercle bacilli. 1. A theoretical model for the development of clinical tuberculosis following infection, linking from data on the risk of tuberculous infection and the incidence of clinical tuberculosis in the Netherlands. , 1982, Tubercle.

[30]  S. Ferebee,et al.  A CONTROLLED TRIAL OF ISONIAZID PROPHYLAXIS IN MENTAL INSTITUTIONS. , 1963, The American review of respiratory disease.